

CURRICULUM VITAE



Name: Zhizhuang Joe Zhao

Email: joe-zhao@ouhsc.edu

Phone: +001-405 2719344

Fax: +001-405 2719483

Position: Alfred M. Shideler Professor and Director of Experimental Pathology

Institution: Department of Pathology, University of Oklahoma Health Sciences Center

Location: Oklahoma City, Oklahoma 73104, USA

Education:

- 1979-1984. BS. Department of Chemistry, Jilin University, Changchun, China.
1985-1990. Ph.D. Department of Biochemistry and Biophysics, Oregon State University, Corvallis, Oregon, USA. Mentor: Dr. Sonia Anderson.
1990-1994. Postdoctoral training. Department of Biochemistry, University of Washington, Seattle, Washington, USA. Mentor: Dr. Edmond H. Fischer.

Representative Careers:

- 1994-1995 Research Assistant Professor, Department of Biochemistry, University of Washington, Seattle, USA
1995-2000 Assistant Professor, Division of Hematology/Oncology, Department of Medicine, Department of Biochemistry, Vanderbilt University, Nashville, USA
2000-2005 Associate Professor, Division of Hematology/Oncology, Department of Medicine, Department of Biochemistry, Vanderbilt University, USA
2005–present Alfred M. Shideler Professor and Director of Experimental Pathology, Director of Pathology Graduate Program, Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, USA
2013-present Editor in Chief. Stem Cell Investigation

Specialty & Present Interest:

Protein phosphorylation, cell signaling, cancer, hematological diseases, diabetes, drug screening, antioxidants,

Representative papers (up to 5):

1. Zhao W, Zou K, Farasyn T, Ho WT, Zhao ZJ. Generation and Characterization of a JAK2V617F-Containing Erythroleukemia Cell Line. *PLoS One*. 2014 Jul 18;9(7):e99017.
2. Jin X, Zhao W, Kirabo A, Park SO, Ho WT, Sayeski PP, Zhao ZJ. Elevated Levels of Mast Cells Are Involved in Pruritus Associated with Polycythemia Vera in JAK2V617F Transgenic Mice. *J Immunol*. 2014 Jul 15;193(2):477-84. PMID: 24920845
3. Chen Y, Guo Y, Zhao W, Tina Ho WT, Fu X, Zhao ZJ. Identification of an orally available compound with potent and broad FLT3 inhibition activity. *Oncogene*. 2016 Jun 9;35(23):2971-8.
4. Yue L, Bartenstein M, Zhao W, Ho WT, Han Y, Murdun C, Mailloux AW, Zhang L, Wang X, Budhathoki A, Pradhan K, Rapaport F, Wang H, Shao Z, Ren X, Steidl U, Levine RL, Zhao ZJ*, Verma A*, Epling-Burnette PK*. Efficacy of ALK5 inhibition in myelofibrosis. *JCI Insight*. 2017 Apr 6;2(7):e90932.
5. Bastarache L, Hughey JJ, Hebbring S, Marlo J, Zhao W, Ho WT, Van Driest SL, McGregor TL, Mosley JD, Wells QS, Temple M, Ramirez AH, Carroll R, Osterman T, Edwards T, Ruderfer D,

Velez Edwards DR, Hamid R, Cogan J, Glazer A, Wei WQ, Feng Q, Brilliant M, Zhao ZJ, Cox NJ, Roden DM, Denny JC. Phenotype risk scores identify patients with unrecognized Mendelian disease patterns. *Science*. 2018 Mar 16;359(6381):1233-1239. doi: 10.1126/science.aal4043. PubMed PMID: 29590070; PubMed Central PMCID: PMC5959723.